A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
Taylor, G Jia, H Harrington, K Lee, Lip W Turner, J Ladell, K Price, D Tanday, M Matthews, J Roberts, C
Taylor, G
Jia, H
Harrington, K
Lee, Lip W
Turner, J
Ladell, K
Price, D
Tanday, M
Matthews, J
Roberts, C
Citations
Altmetric:
Abstract
Epstein-Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor antigens. A phase I trial was conducted to demonstrate the safety and immunogenicity of MVA-EL across a range of doses.
Description
Date
2014-08-14
Publisher
Collections
Keywords
Type
Article
Citation
A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. 2014: Clin Cancer Res